Tocilizumab in Chronic Inflammatory CPPD Disease
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD.
The main questions this trial aims to answer are:
* Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease? * Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease?
Participants will receive a monthly infusion of tocilizumab or placebo for three months.
Eligibility criteria
Qualifiers
Adults > 18 years
Diagnosis of CPPD according to ACR/EULAR 2023 classification criteria
Persistent inflammatory pain (> 3 months) or ≥ 2 arthritics/month
Number of painful joints (NAD) > 3
Disqualifiers
Presence of anti-CPP antibodies > 50 IU/ml
Recurrent or chronic infections
History of severe infection (= requiring hospitalization)
Active infection
Trial design
Treatments tested in this trial
- Tocilizumab
- Placebo
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Fresenius AG
Collaborator
Source ClinicalTrials.gov